Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Status and phase

Completed

Phase 2

Conditions

HIV-1 Infection

Treatments

Drug: Dolutegravir

Drug: Lamivudine

Study type

Interventional

Funder types

NETWORK

NIH

Identifiers

NCT02582684

ACTG A5353

2UM1AI068636 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

This study was done to see if the combination of two anti-HIV medicines, dolutegravir (DTG, Tivicay) and lamivudine (3TC, Epivir) taken once a day, provide a safe, effective, and well-tolerated treatment for HIV. DTG is a type of HIV medicine called an integrase inhibitor; 3TC is a type of HIV medicine called a reverse transcriptase inhibitor. DTG works by blocking integrase and 3TC works by blocking reverse transcriptase, two HIV proteins (enzymes). This prevents HIV from multiplying and lowers the viral load (amount of HIV in the blood). Both DTG and 3TC are currently part of Food and Drug Administration (FDA) recommended regimens along with a third active drug. Since some HIV medicines have side effects and are costly, there is interest in whether HIV can be successfully controlled with fewer than three HIV drugs.

Full description

This study was a phase II, single-arm, open-label pilot study designed to estimate the efficacy of dolutegravir (DTG) plus lamivudine (3TC) as initial combination ART (antiretroviral therapy) in HIV-1 infected treatment naive participants. The target enrollment was 120 participants with a cap of N=90 participants with screening HIV-1 RNA <= 100,000 copies/mL. The study aimed to enroll >= 20% women. The expected follow-up for each participant was 52 weeks.

Visits occurred at screening, entry, and weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, and 52 from study entry. All signs/symptoms within 30 days prior to entry were recorded. Subsequently, grade 2 or higher rash and all other grade 3 or higher signs and symptoms were recorded. All participants underwent routine monitoring including plasma HIV-1 RNA levels, CD4+ cell count, hematology, chemistry, urinalysis, and pregnancy testing (for women of reproductive potential).

Population-based protease (PR), reverse transcriptase (RT) and integrase genotyping were done at the time of confirmed virologic failure. Plasma samples were stored for potential future studies to assess the impact of adherence, drug-resistant minority viral variants, and DTG exposure on virologic and CD4+ cell count responses to DTG plus 3TC. All participants also underwent UGT1A1 genotyping.

Enrollment

122 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

NOTE: Further information on the eligibility criteria can be found in the study protocol.

Inclusion Criteria:

HIV-1 infection.
Plasma HIV-1 RNA ≥1000 copies/mL and <500,000 copies/mL obtained within 90 days prior to study entry.
No evidence of any RT, any integrase, or major protease resistance mutation (according to the 2014 IAS-USA drug resistance mutations list, available at https://www.iasusa.org/sites/default/files/tam/22-3-642.pdf) based on pre-ARV (antiretroviral) treatment genotype performed any time prior to study entry.
ARV treatment drug-naive (defined as no previous ARV treatment at any time prior to study entry, with the exception of successful post-exposure prophylaxis (PEP) or pre-exposure prophylaxis (PrEP).
The following laboratory values obtained within 45 days prior to study entry:
- ANC (absolute neutrophil count) ≥750/mm^3
- Hemoglobin ≥10.0 g/dL
- Platelets ≥ 50,000/mm^3
- Calculated creatinine clearance (CrCl) ≥50 mL/min, as estimated by the Cockcroft-Gault equation
- AST (aspartate aminotransferase) <5 x ULN (upper limit of normal)
- ALT (alanine aminotransferase) <5x ULN
- Total bilirubin <1.5 x ULN
Hepatitis B surface antigen negative within 45 days prior to study entry.
For women with reproductive potential, negative serum or urine pregnancy test at screening and within 48 hours prior to study entry.
If participating in sexual activity that could lead to pregnancy, female participants with reproductive potential must have agreed to use one form of contraceptive as listed in the protocol while receiving protocol-specified medications and for 30 days after stopping the medications.
Ability and willingness of participant or legal representative to provide informed consent.

Exclusion Criteria:

Serious illness requiring systemic treatment and/or hospitalization.
Treatment within 30 days prior to study entry with immune modulators such as systemic steroids, interleukins, interferons, granulocyte colony-stimulating factor (G-CSF), erythropoietin, or any investigational therapy.
Pregnancy or breastfeeding.
Receipt of systemic cytotoxic chemotherapy or dofetilide.
Known allergy/sensitivity to any of the study drugs or their formulations.
Active drug or alcohol use or dependence that may interfere with adherence to study requirements, in the opinion of the site investigator.
Active hepatitis C virus (HCV) treatment or anticipated need for treatment within study period.
Unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice), known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
Severe hepatic impairment (Class C) as determined by Child-Pugh classification.